Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot shows promise against tough skin cancer

NCT ID NCT06041802

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination (pembrolizumab plus berahyaluronidase alfa) given as a shot under the skin for Japanese patients with advanced squamous cell skin cancer that has spread or cannot be removed by surgery. The main goal is to see if the treatment can shrink tumors. About 19 people will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 skin squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

  • Cancer Institute Hospital of JFCR ( Site 0018)

    Koto, Tokyo, 135-8550, Japan

  • Chiba University Hospital ( Site 0001)

    Chiba, 260-8677, Japan

  • Keio University Hospital ( Site 0010)

    Tokyo, 1608582, Japan

  • Nagoya University Hospital ( Site 0003)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital ( Site 0007)

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Hospital Organization Kagoshima Medical Center ( Site 0013)

    Kagoshima, 892-0853, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 0017)

    Fukuoka, 811-1395, Japan

  • Niigata Cancer Center Hospital ( Site 0005)

    Niigata, Niigata, 951-8566, Japan

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0009)

    Osaka, 541-8567, Japan

  • Saitama Medical University International Medical Center ( Site 0008)

    Hidaka, Saitama, 350-1298, Japan

  • Sapporo Medical University Hospital ( Site 0002)

    Sapporo, Hokkaido, 060-8543, Japan

  • Shimane University Hospital ( Site 0014)

    Izumo, Shimane, 693-8501, Japan

  • Shinshu University Hospital ( Site 0011)

    Matsumoto, Nagano, 390-8621, Japan

  • Shizuoka Cancer Center ( Site 0004)

    Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan

  • Tohoku University Hospital ( Site 0019)

    Sendai, Miyagi, 980-8574, Japan

  • University Hospital,Kyoto Prefectural University of Medicine ( Site 0012)

    Kyoto, 602-8566, Japan

  • Wakayama Medical University Hospital ( Site 0015)

    Wakayama, 641-8510, Japan

  • Yokohama City University Hospital ( Site 0016)

    Yokohama, Kanagawa, 236-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.